We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
Pinnacle West Capital
PNW
$11.5B
| $9.34M | 0.02% |
122,329
-8,647
| -7% | -$653K |
|
577
Itron
ITRI
$4.03B
| $9.34M | 0.02% |
94,406
-22,639
| -19% | -$2.28M |
|
578
Ardmore Shipping
ASC
$779M
| $9.33M | 0.02% |
413,954
+275
| +0.1% | +$5.42K |
|
579
SiriusPoint
SPNT
$2.84B
| $9.3M | 0.02% |
762,068
-917
| -0.1% | -$11.4K |
|
580
Burford Capital
BUR
$850M
| $9.13M | 0.02% |
699,353
-102,441
| -13% | -$1.5M |
|
|
BRSP
581
BrightSpire Capital
BRSP
$543M
| $9.05M | 0.02% |
1,588,384
+6,297
| +0.4% | +$38.7K |
|
582
Equinix
EQIX
$100B
| $9.04M | 0.02% |
11,954
+49
| +0.4% | +$37.2K |
|
583
Dream Finders Homes
DFH
$1.09B
| $9.01M | 0.02% |
348,800
-26,200
| -7% | -$828K |
|
584
Clorox
CLX
$10.3B
| $8.98M | 0.02% |
65,810
+7,916
| +14% | +$1.1M |
|
|
RDFN
585
DELISTED
Redfin
RDFN
| $8.94M | 0.02% |
1,488,228
-10,761
| -0.7% | -$67.2K |
|
586
Fortis
FTS
$27.5B
| $8.93M | 0.02% |
229,876
-15,099
| -6% | -$595K |
|
587
Alcon
ALC
$32B
| $8.91M | 0.02% |
100,070
-33,674
| -25% | -$2.87M |
|
588
Okta
OKTA
$32.9B
| $8.8M | 0.02% |
94,049
+88,848
| +1,708% | +$8.41M |
|
589
Infosys
INFY
$44.9B
| $8.7M | 0.02% |
467,207
+92,458
| +25% | +$1.61M |
|
590
Upbound Group
UPBD
$1.04B
| $8.69M | 0.02% |
283,192
-699
| -0.2% | -$22.3K |
|
591
Albemarle
ALB
$12.9B
| $8.69M | 0.02% |
90,964
+76,051
| +510% | +$9.04M |
|
592
InterDigital
IDCC
$8.48B
| $8.62M | 0.02% |
73,925
+877
| +1% | +$93.7K |
|
593
Dynatrace
DT
$16B
| $8.54M | 0.02% |
190,875
-121,298
| -39% | -$5.59M |
|
594
SCYNEXIS
SCYX
$40.9M
| $8.43M | 0.02% |
526,838
| – | – |
|
595
Huron Consulting
HURN
$2.45B
| $8.41M | 0.02% |
85,357
-25
| -0% | -$2.3K |
|
|
RPC
596
Ridgepost Capital
RPC
$872M
| $8.36M | 0.02% |
985,708
-1,614,292
| -62% | -$12.9M |
|
597
Medpace
MEDP
$17.2B
| $8.13M | 0.02% |
19,736
+771
| +4% | +$305K |
|
598
MetLife
MET
$61.8B
| $8.09M | 0.02% |
115,224
+2,749
| +2% | +$196K |
|
599
AbCellera Biologics
ABCL
$3.78B
| $8.07M | 0.02% |
2,726,016
-89,443
| -3% | -$338K |
|
600
SunCoke Energy
SXC
$816M
| $8.04M | 0.02% |
820,731
+2,335
| +0.3% | +$24.1K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.